Bio-Techne Corporation (TECH) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
44.09
+8% vs avg
5yr avg: 40.64
30Y Low13.0·High56.8
P/FCF
↓
35.36
↓-30% vs avg
5yr avg: 50.38
30Y Low20.1·High83.7
P/B Ratio
↓
4.82
↓-34% vs avg
5yr avg: 7.31
30Y Low3.5·High19.4
ROE
↓
3.7%
↑-66% vs avg
5yr avg: 10.7%
30Y Low4%·High27%
Debt/EBITDA
↑
2.09
↑+58% vs avg
5yr avg: 1.33
30Y Low0.1·High2.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TECH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bio-Techne Corporation trades at 126.0x earnings, 54% above its 5-year average of 81.6x, sitting at the 97th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 469%. On a free-cash-flow basis, the stock trades at 35.4x P/FCF, 30% below the 5-year average of 50.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.1B | $8.2B | $11.5B | $13.2B | $14.2B | $18.2B | $10.4B | $8.1B | $5.6B | $4.4B | $4.2B |
| Enterprise Value | $9.4B | $8.5B | $11.8B | $13.5B | $14.4B | $18.5B | $10.7B | $8.5B | $5.8B | $4.7B | $4.3B |
| P/E Ratio → | 125.96 | 111.85 | 68.24 | 46.38 | 52.20 | 129.39 | 45.53 | 84.06 | 45.11 | 56.50 | 40.27 |
| P/S Ratio | 7.44 | 6.74 | 9.94 | 11.62 | 12.86 | 19.58 | 14.09 | 11.36 | 8.76 | 7.83 | 8.43 |
| P/B Ratio | 4.82 | 4.28 | 5.57 | 6.72 | 8.36 | 11.60 | 7.53 | 6.96 | 5.22 | 4.63 | 4.79 |
| P/FCF | 35.36 | 32.03 | 48.79 | 61.13 | 50.73 | 59.21 | 67.80 | 51.91 | 37.68 | 34.36 | 33.15 |
| P/OCF | 31.55 | 28.58 | 38.53 | 51.94 | 43.72 | 51.76 | 50.70 | 44.64 | 33.05 | 30.72 | 29.25 |
P/E links to full P/E history page with 30-year chart
TECH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bio-Techne Corporation's enterprise value stands at 44.1x EBITDA, 8% above its 5-year average of 40.6x. The Healthcare sector median is 14.2x, placing the stock at a 210% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.97 | 10.17 | 11.86 | 13.00 | 19.82 | 14.47 | 11.92 | 9.09 | 8.29 | 8.57 |
| EV / EBITDA | 44.09 | 40.06 | 37.02 | 33.20 | 36.15 | 56.76 | 44.52 | 41.78 | 29.14 | 25.66 | 22.13 |
| EV / EBIT | 91.47 | 79.45 | 58.52 | 38.55 | 45.97 | 113.80 | 36.16 | 63.66 | 42.95 | 39.10 | 28.67 |
| EV / FCF | — | 33.13 | 49.92 | 62.40 | 51.28 | 59.93 | 69.67 | 54.49 | 39.13 | 36.37 | 33.70 |
TECH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Bio-Techne Corporation earns an operating margin of 8.4%. Operating margins have compressed from 26.3% to 8.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 3.7% is modest. ROIC of 3.4% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% | 67.5% |
| Operating Margin | 8.4% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% | 30.2% |
| Net Profit Margin | 6.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% | 20.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 3.7% | 3.7% | 8.3% | 15.6% | 16.6% | 9.5% | 18.0% | 8.6% | 12.3% | 8.4% | 12.1% |
| ROA | 2.8% | 2.8% | 6.3% | 11.6% | 11.9% | 6.5% | 11.7% | 5.5% | 8.0% | 5.8% | 9.5% |
| ROIC | 3.4% | 3.4% | 6.8% | 10.9% | 12.2% | 10.3% | 7.3% | 6.6% | 8.2% | 8.5% | 12.2% |
| ROCE | 4.2% | 4.2% | 8.2% | 12.9% | 14.0% | 11.8% | 8.5% | 7.6% | 9.3% | 9.8% | 14.3% |
TECH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Bio-Techne Corporation carries a Debt/EBITDA ratio of 2.1x, which is manageable (35% below the sector average of 3.2x). Net debt stands at $282M ($444M total debt minus $162M cash). Interest coverage of 12.6x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 0.20 | 0.23 | 0.19 | 0.27 | 0.31 | 0.43 | 0.31 | 0.37 | 0.15 |
| Debt / EBITDA | 2.09 | 2.09 | 1.32 | 1.12 | 0.82 | 1.29 | 1.81 | 2.48 | 1.69 | 1.92 | 0.69 |
| Net Debt / Equity | — | 0.15 | 0.13 | 0.14 | 0.09 | 0.14 | 0.21 | 0.35 | 0.20 | 0.27 | 0.08 |
| Net Debt / EBITDA | 1.33 | 1.33 | 0.84 | 0.68 | 0.39 | 0.68 | 1.19 | 1.98 | 1.08 | 1.42 | 0.36 |
| Debt / FCF | — | 1.10 | 1.13 | 1.27 | 0.55 | 0.72 | 1.87 | 2.59 | 1.45 | 2.01 | 0.55 |
| Interest Coverage | 12.57 | 12.57 | 12.80 | 31.20 | 27.65 | 11.62 | 15.40 | 6.16 | 13.36 | 16.21 | 85.37 |
TECH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Bio-Techne Corporation's current ratio of 3.46x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.38x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 4.84x to 3.46x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.46 | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 | 4.88 | 4.05 | 5.06 | 2.55 | 4.69 |
| Quick Ratio | 2.38 | 2.38 | 2.75 | 3.50 | 2.64 | 2.59 | 3.92 | 3.15 | 3.97 | 2.11 | 3.63 |
| Cash Ratio | 0.92 | 0.92 | 0.96 | 1.59 | 1.40 | 1.52 | 2.54 | 1.63 | 2.31 | 1.17 | 1.77 |
| Asset Turnover | — | 0.48 | 0.43 | 0.43 | 0.48 | 0.41 | 0.36 | 0.38 | 0.40 | 0.36 | 0.44 |
| Inventory Turnover | 2.27 | 2.27 | 2.17 | 2.14 | 2.47 | 2.55 | 2.48 | 2.64 | 2.46 | 3.13 | 2.84 |
| Days Sales Outstanding | — | 61.91 | 76.02 | 70.15 | 64.23 | 57.00 | 60.55 | 70.27 | 68.29 | 75.74 | 68.31 |
TECH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bio-Techne Corporation returns 3.6% to shareholders annually — split between a 0.5% dividend yield and 3.0% buyback yield. A payout ratio of 68.7% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 0.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.5% | 0.6% | 0.4% | 0.4% | 0.4% | 0.3% | 0.5% | 0.6% | 0.9% | 1.1% | 1.1% |
| Payout Ratio | 68.7% | 68.7% | 30.0% | 17.6% | 18.4% | 35.3% | 21.3% | 50.3% | 38.3% | 61.2% | 45.6% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.8% | 0.9% | 1.5% | 2.2% | 1.9% | 0.8% | 2.2% | 1.2% | 2.2% | 1.8% | 2.5% |
| FCF Yield | 2.8% | 3.1% | 2.0% | 1.6% | 2.0% | 1.7% | 1.5% | 1.9% | 2.7% | 2.9% | 3.0% |
| Buyback Yield | 3.0% | 3.4% | 0.7% | 0.1% | 1.1% | 0.2% | 0.5% | 0.2% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 3.6% | 4.0% | 1.1% | 0.5% | 1.5% | 0.5% | 1.0% | 0.8% | 0.9% | 1.1% | 1.1% |
| Shares Outstanding | — | $160M | $161M | $162M | $164M | $162M | $158M | $156M | $152M | $150M | $149M |
Peer Comparison
Compare TECH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TECHYou | $9B | 126.0 | 44.1 | 35.4 | 64.8% | 8.4% | 3.7% | 3.4% | 2.1 |
 RGEN | $7B | 153.5 | 54.7 | 79.3 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 NEOG | $2B | -1.9 | 20.8 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 AZTA | $1B | -19.1 | 18.1 | 28.0 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 RVTY | $11B | 48.1 | 20.9 | 22.0 | 53.1% | 12.5% | 3.2% | 2.7% | 5.3 |
 MESO | $2B | -17.1 | — | — | 70.2% | -363.1% | -19.0% | -8.5% | — |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 BIO | $8B | 10.1 | 18.1 | 20.4 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 QGEN | $8B | 18.1 | 11.8 | 16.8 | 61.8% | 24.9% | 11.6% | 8.6% | 2.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
TECH — Frequently Asked Questions
Quick answers to the most common questions about buying TECH stock.
What is Bio-Techne Corporation's P/E ratio?
Bio-Techne Corporation's current P/E ratio is 126.0x. The historical average is 44.6x. This places it at the 97th percentile of its historical range.
What is Bio-Techne Corporation's EV/EBITDA?
Bio-Techne Corporation's current EV/EBITDA is 44.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.8x.
What is Bio-Techne Corporation's ROE?
Bio-Techne Corporation's return on equity (ROE) is 3.7%. The historical average is 17.6%.
Is TECH stock overvalued?
Based on historical data, Bio-Techne Corporation is trading at a P/E of 126.0x. This is at the 97th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Bio-Techne Corporation's dividend yield?
Bio-Techne Corporation's current dividend yield is 0.54% with a payout ratio of 68.7%.
What are Bio-Techne Corporation's profit margins?
Bio-Techne Corporation has 64.8% gross margin and 8.4% operating margin.
How much debt does Bio-Techne Corporation have?
Bio-Techne Corporation's Debt/EBITDA ratio is 2.1x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.